LIMINATUS PHARMA ENGAGES SYNEX AS CONTRACT RESEARCH ORGANIZATION TO SUPPORT PHASE 1/2A CLINICAL DEVELOPMENT OF CD19XCD22 BIVALENT CAR-T THERAPY

Reuters · 2d ago

Please log in to view news